HiberCell is a biotechnology company dedicated to developing therapeutic molecules that address the biology and mechanisms of tumor dormancy. The company focuses on overcoming foundational barriers that prevent patients from living longer, cancer-free lives. HiberCell operates in the oncology market, serving patients and healthcare providers by offering innovative treatments aimed at modulating tumor dormancy. The business model revolves around research and development of novel therapies, securing funding through venture capital and debt facilities, and forming strategic collaborations for diagnostic discovery and commercialization. Revenue is generated through the development and eventual commercialization of these therapeutic solutions. HiberCell's recent financial activities include closing a $67.4 million Series B financing and securing a $30 million debt facility from Hercules Capital. The company also collaborates with Biodesix for companion diagnostic discovery and development.

Keywords: tumor dormancy, therapeutic molecules, oncology, cancer-free, biotechnology, venture capital, strategic collaborations, diagnostic discovery, healthcare providers, innovative treatments.